COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE IN THE MANAGEMENT OF TYPE 1 AND TYPE 2 DIABETES MELLITUS FROM THE SPANISH NATIONAL HEALTH SYSTEM PERSPECTIVE

被引：0

作者：

Ramirez de Arellano, A. ^{[1
]}

Mezquita, P. ^{[2
]}

Darba, J. ^{[3
]}

机构：

[1] Novo Nordisk, Madrid, Spain

[2] Hosp Torrecardenas, Almeria, Spain

[3] Univ Barcelona, Barcelona, Spain

来源：

VALUE IN HEALTH | 2016年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB47

引用

页码：A673 / A673

页数：1

共 50 条

[1] Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective
Mezquita-Raya, Pedro
Darba, Josep
Ascanio, Meritxell
Ramirez de Arellano, Antonio
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (06) : 587 - 595
[2] Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective (vol 17, pg 587, 2017)
Mezquita-Raya, P.
Darba, J.
Ascanio, M.
Ramirez de Arellano, A.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (06) : I - I
[3] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC COMPARED WITH CURRENT STANDARD OF CARE IN THE MANAGEMENT OF TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE SPANISH HEALTH SYSTEM
Ramirez de Arellano, A.
Orozco-Beltran, D.
Mezquita-Raya, P.
Perez, A.
Galan, M.
VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
[4] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
Marc Evans
Barrie Chubb
Jens Gundgaard
Diabetes Therapy, 2017, 8 : 275 - 291
[5] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
Evans, Marc
Chubb, Barrie
Gundgaard, Jens
DIABETES THERAPY, 2017, 8 (02) : 275 - 291
[6] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
Evans, M.
Wolden, M.
Gundgaard, J.
Chubb, B.
Christensen, T.
DIABETES OBESITY & METABOLISM, 2014, 16 (04): : 366 - 375
[7] COST-EFFECTIVENESS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATING INSULIN THERAPY IN THE UNITED KINGDOM
Evans, M.
Chubb, B.
Christensen, T.
Gundgaard, J.
Wolden, M.
VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
[8] Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK
Evans, M.
Wolden, M.
Gundgaard, J.
Chubb, B.
Christensen, T.
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (01) : 56 - 68
[9] Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
Monika Russel-Szymczyk
Vasil Valov
Alexandra Savova
Manoela Manova
BMC Endocrine Disorders, 19
[10] Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
Nebojša Lalić
Monika Russel-Szymczyk
Marina Culic
Christian Klyver Tikkanen
Barrie Chubb
Diabetes Therapy, 2018, 9 : 1201 - 1216

← 1 2 3 4 5 →